MicroGen Vet offering is now closed and is no longer accepting investments.

INVEST IN MICROGEN VET TODAY!

DNA-Based Microbial Diagnostic Service

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
MicroGen Vet

$51,390.00 Raised

REASONS TO INVEST

ABOUT

HEADQUARTERS


VALUATION

TEAM

Kurt Dombkowski
Kurt Dombkowski
Founder, CEO, Managing Member

Animal Wound Care World Wide - Founder, CEO - 2014 - 2017 Kurt Dombkowski, MBA, is an award-winning sales executive who has a record of capturing market share by developing loyal relationships with market influencers since 2001. He is a well respected thought leader for directing strategic initiatives, for his superior industry knowledge and competitive product insight. Kurt has over 17 years of sales and brand management experience as a talented director and mentor from his career with Novartis Pharmaceuticals. He has a deep understanding of Cardiovascular and Diabetes Disease State Management earned from his training in conjunction with the Joslin Diabetes Center at the Harvard Medical School. In 2010 Kurt shifted his focus to Wound Care and Infectious Disease management as the Northeast Director with Pioneer Therapeutics. During his time with Pioneer he built key relationships with industry thought leaders, including; the University of Pittsburgh Medical Center's Wound Value and Analysis Team; Dr William Costerton, Director of the Biofilm Research Center for Genomic Sciences at Allegheny Health Network; and Dr Joseph Cacchione, Chairman of Operations and Strategy at the Cleveland Clinic and current President of Ascension Medical Group, the largest non-profit health system in the US. As full time CEO and Managing Member of MicroGen Vet since September 2017, Kurt leverages his extensive knowledge of Wound Care and Biofilm management and relationships build from Animal Wound Care WW to provide business strategy and to oversee sales channel development for the business.

Raymond Ramey
Raymond Ramey
Founder, VP, Managing Member

PhotoPhage Systems LLC - Founder, President 2016 - > Medical diagnostic unit research & development HCC Lens LLC - Founder & President, 2015 - 2017 > Medicare reimbursement software platform Avnet Government Solutions (subsidiary of Avnet Inc.) - General Manager 2012 - 2015) > Public Sector Division for market leading Information Tech product & services distributor Mr. Ramey facilitated the acquisition of Pepperweed Consulting by a publicly traded IT distribution conglomerate. (Fortune 108; $28B annual revenue) in July 2012. Following the acquisition, Mr. Ramey built and ran the company's public sector business and was responsible for business and operational performance of the $850Million/year revenue organization. Ray is an accomplished business executive with a proven track record in finance, strategy, sales, marketing, and operations. Successful business outcomes in diverse industries, geographies and technology markets have been delivered through leadership and ownership roles in both small and large organizations. He is a relationship builder with a record of negotiating complex business relationships and mutually beneficial strategic alliances throughout his career and has been a founder or partner in several startup business ventures resulting in successful exits. As full time VP of Operations and Managing Member for MicroGen Vet since September 2017, Ray provides business acumen and operational skills to develop and drive overall business and operational systems and partnerships. He is responsible for corporate governance and regulatory compliance and oversees funding and investor communications. Mr. Ramey provides ongoing part time advisory services to PhotoPhage Systems ( 5-10 hrs/week). These services will wind down by the end of 2018.

Dr. Bimbo Welker, VMD

Dr. Bimbo Welker, VMD

Advisor

Dr. Welker is the co-Director of Ohio State University’s department for large animal services. The facility is a full service, 24 hour large animal ambulatory and outpatient, urgent care facility. The mission of the operation is to provide services at competitive pricing while teaching students the business and providing an opportunity to practice medicine in a practice setting. He was presented with the Norden Teaching award for his work at the university. Prior to Ohio State University, Dr. Welker was a respected staff surgeon and Surgery Section Chief at Virginia Tech where he was recognized with 11 teaching awards for his leadership. He has also been awarded the Outstanding Speaker Award by the North American Conference and has special areas of interest including practice & wound management, field anesthesia and practical fluid therapy.

Dr. Stephen Reed, DVM

Dr. Stephen Reed, DVM

Advisor

Dr Reed earned his veterinary degree at The University of Ohio. He then completed an internship and residency at Michigan State University. After a period at Washington State University, he returned to The Ohio State University, retiring from there as a professor emeritus in 2007. At the same time he chose a new career path away from academia and is now a shareholder and a member of the Internal Medicine Service at Rood and Riddle Equine Hospital in Lexington, Kentucky. His special interests include Equine Neurology and EPM research.

Dr. Bonnie Barr, VMD DACVIM

Dr. Bonnie Barr, VMD DACVIM

Advisor

Dr. Barr earned her veterinary degree at the University of Pennsylvania. She then completed a one-year internship at Rood and Riddle Equine Hospital and a two-year internal medicine residency at the University of Pennsylvania’s New Bolton Center. Dr. Barr was a staff member for one year at Texas A&M University before rejoining Rood and Riddle Equine Hospital in 2001 as an associate veterinarian specializing in internal medicine. She became boarded in internal medicine in 2003. Her areas of special interest include equine neonatology, equine infectious diseases and infectious disease control. Dr Barr is the co-author of Equine Pediatrics.

Richard Martin

Richard Martin

Advisor

Rick Martin has over 20 years of global business development, marketing, strategy and leadership experience in the healthcare market. This experience spans start-ups to multi-nationals. Mr. Martin had 20 years of experience with Pfizer Pharmaceuticals where he was responsible for Sales operations for Europe and Canada reporting directly to the VP of Europe/Canada, Ian Read, who is the current CEO of Pfizer. Mr. Martin managed a sales organization covering 21 countries and 11,000 sales representatives. Mr. Martin is the Founder of MicroGen DX which is a company formed for the acquisition of PathoGenius in 2016. Mr. Martin is the Chairman and CEO at MicroGen DX and leads its business development efforts for targeted human markets. Beyond the success that Rick has achieved in business, he is also a former Army officer leading high performance teams and achieving Airborne/ Ranger qualification. The attributes he learned while serving our country are the bedrock of his capability as a leader. Mr. Martin received his Bachelors of Arts from the University of Massachusetts (Amherst). Mr. Martin provides technology and diagnostics strategy advisory services to MicroGen Vet and shares his knowledge with Veterinary Research Universities and other key customers in support of MicroGen Vet.

TERMS

MicroGen Vet
Overview
PRICE PER SHARE
DEADLINE
Sep 29, 2018
VALUATION
AMOUNT RAISED
$51,390.00
Breakdown
MIN INVESTMENT
MAX INVESTMENT
MIN NUMBER OF SHARES OFFERED
OFFERING TYPE
Equity
ASSET TYPE
SHARES OFFERED
MAX NUMBER OF SHARES OFFERED

Maximum Number of Shares Offered subject to adjustment for bonus shares

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000:

ALL UPDATES

09.25.18

Final Week to Invest in MicroGen Vet!!!

We certainly hope to see many of those following MicroGen Vet on StartEngine convert to investors this week as Friday is our last day on the platform.  Don't miss your opportunity to participate!


Thanks everyone for your consideration!


09.17.18

MicroGen Vet is on the move! We’ve been busy – check it out…

MicroGen Vet and NGS has been received warmly and with great interest by many top veterinary research universities – multiple visits and talks planned for the Fall

  • Colorado State (June 2018)
  • Cornell
  • Ohio State
  • Texas A&M
  • Virginia Tech
  • UC Davis

Clinical Trials interest growing rapidly with multiple planned for this Fall

  • EQUINE – Lower Respiratory with Tracheal Wash NGS Study – Rood & Riddle
  • EQUINE – Uterine Infections – Comparison of culture, PCR & NGS – CSU
  • EQUINE – Ophthalmology Fungal Infections NGS Study – Texas A&M
  • EQUINE – Orthopedic Joint Infections NGS Study – Cornell and Rood & Riddle
  • SMALL ANIMAL – Dermatology NGS Study – Texas Specialist Clinic
  • SMALL ANIMAL - Ophthalmology Infections NGS Study – Ohio State
  • SMALL ANIMAL – Spinal Fluid NGS Study – Florida Emergency Clinic
  • Others are in discussion

Services have been picked up my multiple leading distribution and resale partners

  • MWI Animal Health
  • Miller Vet Supply
  • VetCove
  • Henry Schein (to be finalized in Sep 2018)
  • Others are planned for 2019

Branding and market reach

  • Over 100,000+ reached and 3,300 website visits driven through Facebook, LinkedIn and Twitter advertising
  • www.microgenvet.com website expanded with clinical papers and videos

Expanding clinical support network

  • Dr. Barr – Equine, Rood & Riddle
  • Dr. Reed - Equine, Rood & Riddle
  • Dr. Rossi – Small Animal, Houston TX
  • Dr. Welker – Equine & Livestock, OSU
  • Dr. Song – Small Animal, Phoenix AZ
  • Dr. Brown – Equine, VT
  • Dr. Metzler – Equine & Small Animal, OSU

Expanding sales support network

  • Northern and Southern California
  • Wyoming, Utah, Idaho, North & South Dakota
  • St. Louis, MO
  • Florida
  • North Carolina
  • Georgia
  • Tennessee
  • Active posting of additional positions around the country

Funding plan still in process

  • StartEngine crowdfunding will come to an end on Sep 28, 2018 for non-accredited investor participation
  • Parallel large accredited investor funding round will commence in Oct 2018

We need your support to provide short term funding in order to continue our push for market education and for recruitment of additional sales support resources to support our distribution partners.  We also plan to participate in several trade shows including AAEP and VMX.  Your investment will support MicroGen Vet as we continue to implement our business model while we secure significant funding for growth through 2019.  Don’t miss this opportunity to participate – it won’t come again!!!  We want folks who are passionate about animal health to join our journey!!! 

09.06.18

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, MicroGen Vet has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in MicroGen Vet be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

08.10.18

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, MicroGen Vet has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in MicroGen Vet be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$51,390.00
INVESTORS
54
MIN INVEST
VALUATION

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.